REGN23415 / Regeneron - LARVOL DELTA

REGN23415 and REGN24493: In-Vitro Properties of Two Novel TSHR-Blocking Monoclonal Antibodies for the Treatment of Graves' Disease and Thyroid Eye Disease (ATA 2026) - No abstract available

Preclinical • Endocrine Disorders • Grave’s Disease • Ophthalmology • Thyroid Eye Disease

A Novel TSHR-Blocking Antibody Which Effectively Reduces Hyperthyroidism and Proptosis in a Mouse Model of Graves’ and Thyroid Eye Disease (ETA 2026) - "These findings demonstrate that chronic M22 injections alone can induce both hyperthyroidism and proptosis in female mice. TSHR blockade effectively reduced hyperthyroidism and prevented TSAb-induced proptosis. These results suggest that REGN23415 and REGN24493 are potent TSHR blockers with therapeutic potential for GD and TED."

Preclinical • Endocrine Disorders • Grave’s Disease • Immunology • Ophthalmology • Thyroid Eye Disease • TSHR